Characterization of Pulmonary Microbiome in Cystic Fibrosis Patients

Study Overview
=================
Brief Summary
-----------------
The composition and role of the pulmonary microbiota is not yet well described in cystic fibrosis patients. The objective of our longitudinal follow-up of primary colonised patients is to show the presence of a link between the composition of the microbiota and the effectiveness of antibiotic therapy. All patients followed at the Montpellier CF center will be asked to participate in this cohort. All patients have a regular follow-up every 1 to 6 months and will be asked at each visit to keep their sputum sample in excess of the analyses requested for their follow-up

Detailed Description
-----------------
The composition and role of the pulmonary microbiota is not yet well described in cystic fibrosis patients. According to our hypothesis, the lung microbiota shapes the lung environment of cystic fibrosis patients and modifies the effectiveness of antibiotic treatments and the course of the disease. The objective of our longitudinal follow-up of primary colonised patients is to show the presence of a link between the composition of the microbiota and the effectiveness of antibiotic therapy. Finally, the management of first colonisations could justify the characterisation of the microbiota in order to develop innovative diagnostic tests for the follow-up of patients suffering from cystic fibrosis and possibly the identification of new therapeutic agents based on the microbiota. All patients followed at the Montpellier CF centre will be asked to participate in this cohort. All patients have a regular follow-up every 1 to 6 months and will be asked at each visit to keep their sputum sample in excess of the analyses requested for their follow-up.

Official Title
-----------------
Multi-omic Longitudinal Characterization of Pulmonary Microbiome in Cystic Fibrosis Patients

Conditions
-----------------
Cystic Fibrosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: - Cystic fibrosis patient Exclusion criteria - Refusal to participate in this research
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to determine a characterisation of the microorganisms of the lung microbiota | to characterise the microorganisms of the lung microbiota and their interspecific interactions by taxonomic and functional analyses. | 1 day | 
| to determine a ink between the Composition of the microbiota | To demonstrate the relationship between the composition of the microbiota and the evolution of the disease Defines the effectiveness of anti-inflammatory biotherapy in patients with cystic fibrosis | 1 day | 
| to determine a Effectiveness of antibiotic therapy | To identify abiotic conditions that may contribute to the gap between the efficacy of antibiotics in vitro and in vivo. Show that the microbiota plays a role in the effectiveness of antibiotic treatment. | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MICROBIOLOGY, MULTI-OMIC, SPUTUM, PULMONARY MICROBIOTA, CYSTIC FIBROSIS, COHORT, ANTIBIOTHERAPY